taXonomy Pathways

taXonomy Pathways is a data product from HealthVerity that combines closed payer claims, lab results, structured EHR data, and physician notes to construct longitudinal patient journeys. It is designed for life sciences researchers who need evidence that goes beyond what claims data alone can provide, particularly when studying treatment patterns, disease progression, and outcomes across therapeutic areas.

The product is built on a claims foundation covering 300 payers, 350 million patients, and nine years of history. This is connected to hospital and ambulatory EHR records, billions of lab results, and more than 3.6 billion physician notes linked to 43 million patients. The datasets are structured in a relational model intended to reduce data wrangling and accelerate the path from raw data to research findings.

Core Capabilities

• Unifies closed payer claims across hundreds of payers with lab results, structured EHR, and physician notes into a single relational dataset.
• Covers 350 million patients with nine years of longitudinal claims history across multiple pay types.
• Connects claims to billions of lab results and more than 3.6 billion physician notes linked to 43 million patients.
• Includes both hospital and ambulatory EHR data for multi-setting coverage.
• Provides near-complete cost detail to support outcomes and economic analyses.
• Offers transparent sourcing and stable data supply to support reproducible and consistent findings.
• Streamlined data model is designed to minimize preparation time and accelerate time to evidence.

Therapeutic Area Pathways

• Alzheimer's: Cognitive scores such as MMSE or MoCA from EHR, caregiver observations and behavioral symptoms from physician notes, and labs including APOE genotyping and beta-amyloid markers, combined with imaging claims, to track patients from diagnosis through therapy progression.
• Ulcerative Colitis (UC): Disease activity scores including Mayo and partial Mayo index, notes capturing symptom flares and patient-reported quality of life, and labs such as CRP, fecal calprotectin, and hemoglobin to monitor inflammation and anemia across treatment settings.
• Obesity / GLP-1: Repeated BMI, weight, and blood pressure measurements over time, notes detailing lifestyle interventions, adherence, and side effects, and labs including HbA1c, lipid panels, and liver enzymes to identify comorbidities such as diabetes and NASH and assess the full impact of GLP-1 therapy.
• Congestive Heart Failure (CHF): Ejection fraction values and NYHA class from EHR, notes capturing dyspnea, edema, and fatigue, and labs including NT-proBNP, troponin, and renal panels, alongside claims reflecting hospitalizations, devices, and long-term therapy adoption.
• Psoriasis: Severity measures such as PASI and body-surface-area involvement from EHR, notes covering patient-reported symptoms and treatment response, and CRP and lipid panels to monitor systemic inflammation and cardiovascular risk.
• Custom therapeutic areas: The platform supports configuration for additional conditions, connecting claims, labs, EHR, and notes to build longitudinal evidence in any therapeutic area.

Research Benefits

• Enables study of patient journeys with depth and continuity through longitudinal, multi-source data integration.
• Supports closure of therapeutic evidence gaps that cannot be addressed with claims data alone.
• Provides representative data across therapeutic areas to support generalizable findings.
• Delivers consistent and reproducible evidence through stable data supply and transparent sourcing.

taXonomy Pathways is offered by HealthVerity and is accessible through the HealthVerity platform. Researchers interested in specific therapeutic area configurations or broader deployment options can engage directly with HealthVerity to explore pathway options tailored to their study needs.